CHatgpt summary & Analysis

Abstract

Methods for treating tissue with irreversible electroporation and immunotherapy are described. The methods include placing a probe in tissue within a human body, wherein the probe has at least a first electrode, applying a plurality of electrical pulses through the first electrode and a second electrode, causing irreversible electroporation (IRE) of the tissue within a target ablation zone, and administering one or more exogenous agents into the tissue within the target ablation zone or to the human, thereby stimulating or otherwise modulating an immune system response within the body.

Claims

A method for treating tissue comprising: applying a plurality of electrical pulses with: a pulse length of 1 second or less; a frequency of 10-100 kHz; and a voltage of at least 500 V; causing electroporation of cells; and promoting an immune response within a body in a manner that causes death of metastases by way of immune cells that respond to the applied electrical pulses.
The method of claim 1, wherein the electrical pulses have a pulse length of between 1 picosecond-100 microseconds.
The method of claim 1, wherein the electrical pulses have a pulse length of between 1 picosecond-10 microseconds.
The method of claim 1, wherein the electrical pulses have a pulse length of 10 microseconds or less.
The method of claim 1, wherein the electrical pulses are applied as a pulse train comprising bursts of pulses.
The method of claim 5, wherein the electrical pulses are applied with a delay between one or more pulses and/or between one or more bursts.
The method of claim 1, wherein one or more of the electrical pulses are biphasic and have a pulse length of 10 microseconds or less.
The method of claim 1, wherein at least two adjacent pulses are biphasic and comprise a delay of up to 5 times the pulse length between the adjacent pulses.
The method of claim 8, wherein the two adjacent pulses comprise a first pulse and a second pulse each with a pulse length of 10 microseconds or less.
The method of claim 9, wherein the delay is up to 5 microseconds, 10 microseconds, or 20 microseconds in length.
The method of claim 1, wherein the immune response is promoted by immune cells present in a first target ablation zone.
The method of claim 11, wherein the immune response is promoted by immune cells present in a second zone disposed in a region beyond the first zone.
The method of claim 11, wherein the immune response is promoted by immune cells present in the first target ablation zone and a second zone disposed in a region beyond the first zone.
The method of claim 11, wherein a second zone is disposed beyond the first zone and a different immune response occurs in the second zone as compared with that in the first zone.
The method of claim 1, wherein the electroporation comprises reversible electroporation (RE), irreversible electroporation (IRE), electrochemotherapy (ECT), electrogenetherapy (EGT), or combinations thereof.
The method of claim 1, further comprising: delivering an agent after applying the electrical pulses; and delivering reversible electroporation after delivering the agent.
The method of claim 1, further comprising: administering one or more exogenous or endogenous agents, wherein the exogenous or endogenous agents indicate a response to treatment; and upon indication of a response to treatment, applying additional electrical pulses.
The method of claim 17, wherein the response to treatment is indicated by one or more of cell proliferation, a reduction in cell proliferation, or a stimulating of or otherwise modulating of an immune system response within the body.
The method of claim 17, wherein the one or more exogenous or endogenous agents comprises a contrast agent, a radioisotope, a natural protein, a synthetic protein, a natural peptide, synthetic peptide, a peptidomimetic, an antibody, an antibody fragment, an antibody conjugate, a nucleic acid, an siRNA, antisense RNA, an aptamer, a ribozyme, or oligonucleotide, a viral vector comprising a nucleic acid, a bioactive agent, a cancer therapeutic agent, a chemotherapy agent, a targeted cancer therapy agent, a differentiating therapy agent, a hormone therapy agent, an immunotherapy agent, monoclonal antibody therapies, non-specific immunotherapies and adjuvants, immunomodulating drugs, cancer vaccines, an engineered cell, or combinations thereof.
The method of claim 1, further comprising determining if there is a response to treatment.

Patent Status Updating...

Oops! Something went wrong while submitting the form.

Patent Status Updating...

Oops! Something went wrong while submitting the form.

CAGR:

10

# LPs Interested:

1

Competition:

USPTO

View Patent

Tech Transfer

View Offering

Market Category & Size

Immunity

$92.8B by 2030

Change Market Category:

Submitting...

Oops! Something went wrong while submitting the form.

Technology Readiness Level

--

Submitting...

Oops! Something went wrong while submitting the form.

Available?

--

Submitting...

Oops! Something went wrong while submitting the form.

Immunotherapeutic methods using electroporation

US-2021022795-A1

LP6

2021-01-28

Virginia Tech

2023-01-01

CHatgpt summary & Analysis

Abstract

Claims

10

1

Immunity

$92.8B by 2030

--

--

Supercharger automates startup research and venture diligence using machine learning and proprietary automation tools. Our suite of software enables faster, more accurate capital allocation and venture lending.